Search results
Results from the WOW.Com Content Network
(Reuters) -GSK has been sued by an independent Connecticut laboratory that accused the drugmaker of defrauding the U.S. government and taxpayers by concealing cancer risks in Zantac, once a ...
News. Shopping. Main Menu. News. News. Entertainment. Lighter Side. ... GlaxoSmithKline — have committed to capping the out-of-pocket cost at $35 a month. GSK’s cap is expected to take effect ...
GSK plc (an acronym from its former name GlaxoSmithKline plc) is a British multinational pharmaceutical and biotechnology company with headquarters in London. [3] [4] It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, [n 1] which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm.
(Reuters) - British drugmaker GSK said on Wednesday it had agreed to settle two lawsuits in California that claimed its discontinued heartburn drug Zantac caused cancer.
British drugmaker GSK cut its forecast for 2024 vaccine sales on Wednesday after quarterly revenue from its blockbuster shingles and respiratory syncytial virus (RSV) jabs missed expectations ...
In the mid-2012, GSK was fined US$3 billion in the United States for misbranding drugs and failing to report drug safety data. [6] Afterwards, GSK entered a five-year agreement with the United States Department of Health and Human Services to reform its compensation policy which tied bonuses to sales targets and providing perverse incentives for misconduct.
United States v. GlaxoSmithKline was a case before the United States District Court for the Eastern District of Pennsylvania.Robert J. Merena was one of the first who filed claims against SmithKline Beecham Clinical Laboratories on November 12, 1993.
GSK on Wednesday raised its full-year profit and sales forecasts for a second time, after better-than-expected quarterly sales of its newly-launched respiratory syncytial virus (RSV) vaccine. GSK ...